- The Company’s shares and warrants to start trading on March 29th, 2022
March 28, 2022 (Source) — Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) (“Valeo” or the “Company“), a Canadian pharmaceutical company, announced today that it has received final approval for the listing of its common shares and warrants on the Toronto Stock Exchange (“TSX“).
The Company’s common shares and warrants will commence trading on the TSX effective as of market open on Tuesday March 29, 2022 (the “Effective Date“), and will continue to trade under the current symbols of “VPH”, “VPH.WT” and “VPH.WT.A. The Company’s commons shares and warrants will concurrently be de-listed from the CSE as of the Effective Date.
“Listing on the TSX, Canada’s senior stock exchange, is an important step supporting our development as a leading Canadian pharmaceutical company”, said Steve Saviuk, CEO. “The TSX platform enhances Valeo’s exposure to a broader investor audience which will benefit all our shareholders”.
About Valeo Pharma
Valeo Pharma is a pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus on Respirology, Neurodegenerative Diseases, Oncology and other specialty products. Headquartered in Kirkland, Quebec, Valeo Pharma has the full capability and complete infrastructure to register and properly manage its growing product portfolio through all stages of commercialization. For more information, please visit www.valeopharma.com and follow us on LinkedIn and Twitter.
Forward Looking Statements
This press release contains forward-looking statements about Valeo’s objectives, strategies and businesses that involve risks and uncertainties. These statements are “forward-looking” because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate.
SOURCE Valeo Pharma Inc.
For further information: Steve Saviuk, CEO, 514-693-8830, [email protected]; Frederic Dumais, Director, Communications and Investor Relations, 514-782-8803, [email protected]
